MERUS N.V. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 46.96 USD | +4.55% |
|
+13.01% | +72.47% |
| 19/04 | Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says | MT |
| 28/03 | Truist Securities Initiates Coverage on Merus With Buy Rating, $69 Price Target | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| MERUS N.V. | Bio Therapeutic Drugs | +5.46% | +13.01% | +72.47% | +149.63% | +202.68% | 2.64B |  |  | |
Technical Rankings Surperformance
- Stock Market
- Equities
- MRUS Stock
- Charts Merus N.V.
- Comparison Chart
